RayBio[®] Human/Mouse/Rat CCK Enzyme Immunoassay Kit

Please Read the Manual Carefully Before Starting your Experiment

User Manual 3.2 (Revised April 16, 2013)

RayBio® CCK Enzyme Immunoassay Kit Protocol

(Cat#: EIA-CCK-1)



We Provide You With Excellent Protein Array System and Service

Tel: (Toll Free) 1-888-494-8555 or 770-729-2992; Fax: 770-206-2393; Web: www.raybiotech.com Email: info@raybiotech.com



RayBio® Human/Mouse/Rat CCK Enzyme Immunoassay Kit Protocol

TABLE OF CONTENTS

I.	Introduction	2	
II.	General Description	3	
III.	Reagents	5	
IV.	Storage	5	
٧.	Additional Materials Required	6	
VI.	Reagent Preparation	6	
VII.	Assay Procedure		
VIII.	Assay Procedure Summary	10	
IX.	Calculation of Results	11	
A.	Typical Data	12	
B.	Sensitivity		
C.	Detection Range	13	
D.	Reproducibility	13	
Χ.	Specificity	13	
XI.	References	13	
ΧII	Troubleshooting Guide	15	

I. INTRODUCTION

Cholecystokinin (CCK) is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein. It is synthesized by I-cells in the mucosal epithelium of the small intestine and secreted in the duodenum, and causes the release of digestive enzymes from the pancreas and bile from the gallbladder.

CCK is a family of hormones identified by number of amino acids depending on post-translational modification of preprocholecystokinin, including CCK58, CCK33 and CCK8. CCK is very similar in structure to another peptide hormone gastrin. They share five identical amino acids at their C-termini.

CCK mediates a number of physiological processes, including digestion and satiety. Secretion of CCK by the duodenal and intestinal mucosa is stimulated by fat- or protein-rich chyme entering the duodenum. It then inhibits gastric emptying and gastric acid secretion and mediates digestion in the duodenum. It stimulates the acinar cells of the pancreas to release water and ions and stimulates the secretion of a juice rich in pancreatic digestive enzymes, hence the old name *pancreozymin*. Together these enzymes catalyze the digestion of fat, protein, and carbohydrates. Thus, as the levels of the substances that stimulated the release of CCK drop, the concentration of the hormone drops as well. The release of CCK is also inhibited by somatostatin.


CCK also causes the increased production of hepatic bile, and stimulates the contraction of the gall bladder and the relaxation of the Sphincter of Oddi (Glisson's sphincter), resulting in the delivery of bile into the duodenal part of the small intestine. Bile salts form amphipathic micelles that emulsify fats, aiding in their digestion and absorption.

II. GENERAL DESCRIPTION

The RayBio® CCK Enzyme Immunoassay (EIA) Kit is an in vitro quantitative assay for detecting CCK peptide based on the principle of Competitive Enzyme Immunoassay.

The microplate in the kit is pre-coated with anti-rabbit secondary antibody. After a blocking step and incubation of the plate with anti-CCK antibody, both biotinylated CCK peptide and peptide standard or targeted peptide in samples interacts competitively with the CCK Uncompeted (bound) biotinylated CCK peptide then interacts with Streptavidin-horseradish peroxidase (SA-HRP), which catalyzes a color development reaction. The intensity of colorimetric signal is directly proportional to the amount of biotinylated peptide-SA-HRP complex and inversely proportional to the amount of CCK peptide in the standard or samples. This is due to the competitive binding to CCK antibody between biotinylated CCK peptide and peptides in standard or samples. A standard curve of known concentration of CCK peptide can established and the be concentration of CCK peptide in the samples can be calculated accordingly.

Principle of Competitive EIA



III. REAGENTS

- 1. CCK Microplate (Item A): 96 wells (12 strips x 8 wells) coated with secondary antibody.
- 2. Wash Buffer Concentrate (20X) (Item B): 25 ml.
- 3. Lyophilized standard CCK peptide (Item C): 2 vials.
- 4. Lyophilized anti-CCK polyclonal antibody (Item N): 2 vials.
- 5. 1X Assay Diluent E (Item R): 2 vials, 25 ml/vial. Diluent for both standards and samples including serum or plasma, cell culture media or other sample types.
- 6. Lyophilized biotinylated CCK peptide (Item F): 2 vials.
- 7. HRP-Streptavidin concentrate (Item G): 600 µl 80x concentrated HRP-conjugated Streptavidin.
- 8. Lyophilized positive control (Item M): 1 vial.
- 10. TMB One-Step Substrate Reagent (Item H): 12 ml of 3, 3', 5, 5'- tetramethylbenzidine (TMB) in buffered solution.
- 11. Stop Solution (Item I): 8 ml of 0.2 M sulfuric acid.
- 12. Assay Diagram (Item J).
- 13. User Manual (Item K).

IV. STORAGE

- Standard, Biotinylated CCK peptide, and Positive Control should be stored at -20 °C after arrival. Avoid multiple freezethaws.
- The remaining kit components may be stored at 4℃.
- Opened Microplate Wells and antibody (Item N) may be stored for up to 1 month at 2° to 8°C. Return unused wells to the pouch containing desiccant pack and reseal along entire edge.
- If stored in this manner, RayBiotech warranties this kit for 6 months from the date of shipment.

V. ADDITIONAL MATERIALS REQUIRED

- 1. Microplate reader capable of measuring absorbance at 450nm.
- 2. Precision pipettes to deliver 2 μl to 1 ml volumes.
- 3. Adjustable 1-25 ml pipettes for reagent preparation.
- 4. 100 ml and 1 liter graduated cylinders.
- 5. Absorbent paper.
- 6. Distilled or deionized water.
- 7. SigmaPlot software (or other software which can perform fourparameter logistic regression models)
- 8. Tubes to prepare standard or sample dilutions.
- 9. Orbital shaker
- 10. Aluminum foil
- 11. Saran Wrap


VI. REAGENT PREPARATION

For sample and positive control dilutions, refer to steps 5, 6, 7 and 9 of Reagent Preparation.

- 1. Keep kit reagents on ice during reagent preparation steps. Equilibrate plate to room temperature before opening the sealed pouch.
- 2. Briefly centrifuge the CCK Antibody vial (Item N) and reconstitute with 5 μl of ddH₂O before use. Add 50 μl of 1x Assay Diluent E into the vial to prepare a detection antibody concentrate. Pipette up and down to mix gently.
- 3. The antibody concentrate should then be diluted 100-fold with 1x Assay Diluent E. This is your anti-CCK antibody working solution, which will be used in step 2 of the Assay Procedure.

NOTE: the following steps may be done during the antibody incubation procedure (step 2 of Assay Procedure).

- 4. Briefly centrifuge the vial of biotinylated CCK peptide (Item F) and reconstitute with 20 μl of ddH₂O before use. Add 10 μl of Item F to 5 ml 1X Assay Diluent E. Pipette up and down to mix gently. The final concentration of biotinylated CCK will be 20 pg/ml. This solution will only be used as the diluent in step 5 of Reagent Preparation.
- 5. Preparation of Standards: Label 6 microtubes with the following concentrations: 1000 pg/ml, 100 pg/ml, 10 pg/ml, 1 pg/ml, 0.1 pg/ml and 0 pg/ml. Pipette 450 μl of biotinylated CCK solution into each tube, except for the 1000 pg/ml (leave this one empty). It is very important to make sure the concentration of biotinylated CCK is 20 pg/ml in all standards.
 - a. Briefly centrifuge the vial of standard CCK peptide (Item C) and reconstitute with 10 μl of ddH₂O. In the tube labeled 1000 pg/ml, pipette 8 μl of Item C and 792 μl of 20 pg/ml biotinylated CCK solution (prepared in step 4 above). This is your CCK stock solution (1000 pg/ml CCK, 20 pg/ml biotinylated CCK). Mix thoroughly. This solution serves as the first standard.
 - b. To make the 100 pg/ml standard, pipette 50 µl of CCK stock solution into the tube labeled 100 pg/ml. Mix thoroughly.
 - c. Repeat this step with each successive concentration, preparing a dilution series as shown in the illustration below. Each time, use 450 µl of biotinylated CCK and 50 µl of the prior concentration until 0.1 pg/ml is reached. Mix each tube thoroughly before the next transfer.
 - d. The final tube (0 pg/ml CCK, 20 pg/ml biotinylated CCK) serves as the zero standard (or total binding).



- 6. Prepare a 10-fold dilution of Item F. To do this, add 2 μ l of Item F to 18 μ l of the 1X Assay Diluent E. This solution will be used in steps 7 and 9.
- 7. Positive Control Preparation: Briefly centrifuge the positive control vial and reconstitute with 100 μl of ddH₂O before use (Item M). To the tube of Item M, add 101 μl 1x Assay Diluent E. Also add 4 μl of 10-fold diluted Item F (prepared in step 6) to the tube. This is a 2-fold dilution of the positive control. Mix thoroughly. The positive control is a cell culture medium sample with an expected signal between 10% and 30% of total binding (70-90% competition) if diluted as described above. It may be diluted further if desired, but be sure the final concentration of biotinylated CCK is 20 pg/ml.
- If Item B (20X Wash Concentrate) contains visible crystals, warm to room temperature and mix gently until dissolved. Dilute 20 ml of Wash Buffer Concentrate into deionized or distilled water to yield 400 ml of 1X Wash Buffer.

9. <u>Sample Preparation</u>: Use 1X Assay Diluent E + biotinylated CCK to dilute samples, including serum/plasma, cell culture medium and other sample types.

It is very important to make sure the final concentration of the biotinylated CCK is 20 pg/ml in every sample. EXAMPLE: to make a 4-fold dilution of sample, mix together 5 μ l of 10-fold diluted Item F (prepared in step 6), 182.5 μ l of 1X Assay Diluent E, and 62.5 μ l of your sample; mix gently. The total volume is 250 μ l, enough for duplicate wells on the microplate.

Do not use Item F diluent from Step 5 for sample preparation. If you plan to use undiluted samples, you must still add biotinylated CCK to a final concentration of 20 pg/ml. EXAMPLE: Add 5 μl of 10-fold diluted Item F to 245 μl of sample. NOTE: Optimal sample dilution factors should be determined empirically, however you may contact technical support (888-494-8555; techsupport@raybiotech.com) to obtain recommended dilution ranges for serum or plasma.

 Briefly centrifuge the HRP-Streptavidin vial (Item G) before use. The HRP-Streptavidin concentrate should be diluted 80fold with 1X Assay Diluent E.

VII. ASSAY PROCEDURE:

- Keep kit reagents on ice during reagent preparation steps. It is recommended that all standards and samples be run at least in duplicate.
- Add 100 μl anti-CCK antibody (see Reagent Preparation step 3) to each well. Incubate for 1.5 hours at room temperature with gentle shaking (1-2 cycles/sec). You may also incubate overnight at 4 degrees C.

- 3. Discard the solution and wash wells 4 times with 1X Wash Buffer (200-300 µl each) Washing may be done with a multichannel pipette or an automated plate washer. Complete removal of liquid at each step is essential to good assay performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
- 4. Add 100 μl of each standard (see Reagent Preparation step 5), positive control (see Reagent Preparation step 7) and sample (see Reagent Preparation step 9) into appropriate wells. Be sure to include a blank well (Assay Diluent only). Cover wells and incubate for 2.5 hours at room temperature with gentle shaking (1-2 cycles/sec) or overnight at 4℃.
- 5. Discard the solution and wash 4 times as directed in Step 3.
- 6. Add 100 µl of prepared HRP-Streptavidin solution (see Reagent Preparation step 10) to each well. Incubate for 45 minutes with gentle shaking at room temperature. It is recommended that incubation time should not be shorter or longer than 45 minutes.
- 7. Discard the solution and wash 4 times as directed in Step 3.
- 8. Add 100 µl of TMB One-Step Substrate Reagent (Item H) to each well. Incubate for 30 minutes at room temperature in the dark with gentle shaking (1-2 cycles/sec).
- 9. Add 50 µl of Stop Solution (Item I) to each well. Read absorbances at 450 nm immediately.

VIII. ASSAY PROCEDURE SUMMARY

1. Prepare all reagents, samples and standards as instructed.

 \prod

2. Add 100 μl anti-CCK antibody to each well. Incubate 1.5 hours at room temperature or overnight at 4°C.

 \int

3. Add 100 μ l standard or sample to each well. Incubate 2.5 hours at room temperature or overnight at 4°C.

 \prod

4. Add 100 μl prepared streptavidin solution. Incubate 45 minutes at room temperature.

5. Add 100 µl TMB One-Step Substrate Reagent to each well. Incubate 30 minutes at room temperature.

 \int

6. Add 50 μl Stop Solution to each well. Read at 450 nm immediately.

IX. CALCULATION OF RESULTS


Calculate the mean absorbance for each set of duplicate standards, controls and samples, and subtract the blank optical density. Plot the standard curve using SigmaPlot software (or other software which can perform four-parameter logistic regression models), with standard concentration on the x-axis and percentage of absorbance (see calculation below) on the y-axis. Draw the best-fit curve through the standard points.

Percentage absorbance = $(B - blank OD)/(B_o - blank OD)$ where B = OD of sample or standard and $B_o = OD$ of zero standard (total binding)

A. TYPICAL DATA

These standard curves are for demonstration only. A standard curve must be run with each assay.

CCK EIA



B. SENSITIVITY

The minimum detectable concentration of CCK is 3.86 pg/ml

C. DETECTION RANGE

0.1-1,000 pg/ml

D. REPRODUCIBILITY

Intra-Assay: CV<10% Inter-Assay: CV<15%

X. SPECIFICITY

Cross Reactivity: This ELISA kit shows no cross-reactivity with any of the cytokines tested: Ghrelin, Nesfatin, NPY and APC.

XI. REFERENCES

- 1. Greenough A, Cole G, Lewis J, Lockton A, Blundell J (1998). "Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion". *Physiol. Behav.* 65 (2): 303–10.
- 2. Fink H, Rex A, Voits M, Voigt JP (1998). "Major biological actions of CCK--a critical evaluation of research findings". *Exp Brain Res* 123 (1-2): 77–83.
- 3. Galés, Céline; Poirot Marc, Taillefer Julien, Maigret Bernard, Martinez Jean, Moroder Luis, Escrieut Chantal, Pradayrol Lucien, Fourmy Daniel, Silvente-Poirot Sandrine (2003). "Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial Cterminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies". Mol. Pharmacol. (United States) 63 (5): 973–82.

4. Gurda, Grzegorz T.; Guo LiLi, Lee Sae-Hong, Molkentin Jeffery D, Williams John A (2008). "Cholecystokinin Activates Pancreatic Calcineurin-NFAT Signaling In Vitro and In Vivo". *Mol. Biol. Cell.* (United States) 19 (198-206): 198–205

XII. TROUBLESHOOTING GUIDE

Problem	Cause	Solution
Poor standard curve	1. Inaccurate pipetting	1. Check pipettes
	2. Improper standard dilution	 Ensure briefly spin the vial of Item C and dissolve the powder thoroughly by a gentle mix.
2. Low signal	1.Too brief incubation times	 Ensure sufficient incubation time; assay procedure step 2 change to over night
	Inadequate reagent volumes or improper dilution	 Check pipettes and ensure correct preparation
3. Large CV	1. Inaccurate pipetting	1. Check pipettes
4. High background	Plate is insufficiently washed	1. Review the manual for proper wash. If using a plate washer, check that all ports are unobstructed.
	Contaminated wash buffer	Make fresh wash buffer
5. Low sensitivity	Improper storage of the EIA kit	 Store your standard at ≤ -20°C after receipt of the kit.
	2. Stop solution	2. Stop solution should be added to each well before measure

RayBio® EIA kits:

If you are interested in other EIA kits, please visit www.raybiotech.com for details.

Notes:

This product is for research use only.



©2013 RayBiotech, Inc.

3607 Parkway Lane, Suite 200 Norcross, GA 30092 Tel: 770-729-2992, 1-888-494-8555 Fax: 770-206-2393

Web: www.raybiotech.com